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Intravaginal (ivag) or intranasal (i.n.) immunization of C57BL/6J (B6) mice with a thymidine kinase-deficient strain (tk) of herpes
simplex virus type 2 (HSV-2) resulted in comparable protection of the genital epithelium and sensory ganglia against HSV-2 challenge. In
contrast, protection of these sites was much reduced in i.n.-immunized compared to ivag-immunized B cell-deficient AMT mice. Fewer HSV-
specific T cells were detected in the genital epithelium of i.n.-immunized compared to ivag-immunized AMT mice after HSV-2 challenge.
Passive transfer of HSV-specific serum to immune AMT mice restored protection of these sites against HSV-2 challenge. These results
suggest that protection of genital and neuronal sites may be conferred by i.n. immunization but may be more dependent on antibody-
dependent mechanisms than the protection resulting from genital immunization. These results have implications for immunization strategies
to elicit high levels of cell-mediated protection of the genital tract and sensory ganglia.
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Genital infection with herpes simplex virus type 2 (HSV-
2) results in virus replication in the genital epithelium, virus
spread to the sensory ganglia, and ultimately results in the
establishment of a latent infection in sensory neurons.
Primary and recurrent lesions associated with HSV-2 infec-
tion are frequently painful and have been associated with
increased risk of acquisition of HIV (Holmberg et al., 1988;
Wasserheit, 1992). Other studies have linked HSV-2 infec-
tion as a cofactor with human papillomavirus infection to
increase the risk of invasive cervical carcinoma (Smith et
al., 2002). Development of effective vaccines against sex-
ually transmitted diseases such as HSV-2 is therefore a high
priority. A number of vaccine types including plasmid DNA
vaccines (Bourne et al., 1996; Kuklin et al., 1997; Sin et al.,
2000), HSV glycoprotein subunits (Corey et al., 1999;0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: gnmillig@utmb.edu (G.N. Milligan).Langenberg et al., 1995; Stanberry et al., 2002), replica-
tion-deficient HSV (Brockman and Knipe, 2002; Morrison
et al., 1998), and recombinant virus vectors (Eo et al., 2001;
Gallichan and Rosenthal, 1998; Kuklin et al., 1998) have
been administered to humans and experimental animals by
systemic and mucosal immunization routes in attempts to
elicit protective immunity within the genital tract.
Immune protection against genital pathogens most likely
requires both antibody- and cell-mediated immune
responses locally in the genital tract. Intravaginal (ivag)
inoculation with attenuated strains of HSV-2 results in
vigorous antigen-specific T and B cell responses in second-
ary lymphoid tissues as well as in the genital tract (McDer-
mott et al., 1984; Milligan and Bernstein, 1995b; Parr et al.,
1998). This model has been extensively used as a paradigm
of protective immunity to examine the immune mechanisms
responsible for protection of the genital epithelium against
HSV-2 infection. While it has been difficult to demonstrate
complete prevention of infection in this model (Kuklin et
al., 1998; Milligan et al., 1998), the immunity elicited by
ivag inoculation of attenuated strains of HSV-2 rapidly
eliminates virus from the vagina and provides a high level
Fig. 1. Clearance of HSV-2 from the genital tracts of mice immunized by
i.n. or ivag routes. Groups of eight B6 mice were immunized by a single
ivag or i.n. inoculation with HSV-2 tk. Four weeks later, immune mice
and eight nonimmune B6 mice were challenged by ivag inoculation with
5  105 PFU HSV-2 strain 186. Vaginal swabs were taken daily to
determine virus titer. Data points marked with asterisks are significantly
different compared to the ivag-immunized group (*P < 0.05; **P < 0.01).
The results shown are from one representative experiment of two
experiments performed.
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(Dudley et al., 2000; Milligan et al., 1998).
In the current study, we compared intranasal (i.n.) and
ivag immunization with a thymidine kinase deficient (tk)
strain of HSV-2 (HSV-2 tk) to determine if the route of
immunization affected the level or mechanism of protection
against HSV-2 challenge of the genital tract. Given the
dependence of protection against HSV-2 infection on T cell
immunity (Milligan et al., 1998), it was important to
determine if effective levels of cell-mediated immunity
could be elicited by immunization at a distal site. The
immune protection of the genital tract as measured by
elimination of challenge virus from the vagina was found
to be comparable between mice immunized by a single i.n.
or ivag inoculation with HSV-2 tk. Further, protection of
the sensory ganglia against acute and latent HSV-2 infection
was comparable in mice immunized by either route. Impor-
tantly, HSV-specific T cells were detected in the genital tract
4 weeks after i.n. immunization although at lower frequen-
cies than ivag-immunized mice. The efficacy of this regional
T cell response elicited by i.n. immunization in protection of
the genital tract and sensory ganglia was directly tested in B
cell-deficient AMT mice. Despite the presence of specific
cell-mediated responses in the vaginal tracts of i.n.-immu-
nized AMT mice, the genital tract and sensory ganglia of
these animals were unprotected against HSV-2 challenge in
contrast to the protection afforded by ivag immunization.
Passive transfer of immune serum to i.n.-immunized AMT
mice reconstituted protection at both sites.
Together, these results complement previous studies
(Gallichan et al., 2001) demonstrating HSV-specific T cell
responses in the genital tract following ivag challenge of
i.n.-immunized mice. The present study extends these
studies by testing the protection afforded to the genital tract
and, importantly, to the sensory ganglia by the cellular
immunity elicited by i.n. immunization. These results also
suggest that immune protection elicited by i.n. immuniza-
tion may be comparable to that of ivag immunization, but
may be more dependent on antibody-mediated mechanisms.Results
Protection of the genital epithelia and sensory ganglia of B6
mice following i.n.- and ivag-immunization
B6 mice were immunized by a single ivag or i.n.
inoculation with HSV-2 tk to determine if the route of
immunization influenced immune protection of the vaginal
epithelium. HSV-specific serum IgG levels were similar
among immunization groups (4.5 F 1.2 Ag/ml for ivag-
immunized and 6.7F 1.1 Ag/ml for i.n.-immunized mice for
the experiment shown in Fig. 1). As we have shown
previously (Milligan et al., 1998), nonimmune mice were
readily infected by vaginal challenge with HSV-2 strain 186
and virus titers remained at high levels through day 6 afterchallenge (Fig. 1). Mice immunized by ivag inoculation
with HSV-2 tk could be reinfected by challenge with fully
virulent HSV-2 strain 186. However, virus titers dropped
rapidly and virus was cleared by day 4 after challenge. Virus
titers were significantly higher only on day 2 after challenge
(P < 0.01) in i.n.-immunized mice compared to ivag-
immunized mice. Challenge virus was eliminated rapidly
thereafter from the genital epithelium of i.n.-immunized
mice and was undetectable by day 6 after challenge.
Infectious virus was readily detected in the sensory
ganglia and spinal cords of all nonimmune mice indicating
rapid neuronal spread and failure to control acute replication
of virus in the sensory ganglia and central nervous systems
(Fig. 2). However, infectious virus was not detected at either
site in ivag- or i.n.-immunized mice on day 8 after chal-
lenge. In a separate experiment, protection against the
establishment of latent infection was assessed by quantify-
ing challenge virus genomes in the sensory ganglia 32 days
after ivag challenge of ivag- or i.n.-immunized mice. HSV-2
strain 186 genomes were below the level of detection by
quantitative PCR analysis (<10 genome copies/100 ng
ganglia DNA) in 8/8 ivag-immunized mice and were de-
tectable at low level (approximately 100 copies/100 ng
ganglia DNA) in only 1/8 i.n.-immunized mice (G. Milli-
gan, unpublished observations). Together, these results
suggested that very effective immune protection of the
sensory ganglia resulted from either i.n. or ivag immuniza-
tion of immunocompetent mice.
Fig. 2. Protection of the sensory ganglia and spinal cords against acute
HSV-2 infection in ivag- or i.n.-immunized B6 mice. Sensory ganglia and
spinal cords were dissected 8 days after ivag HSV-2 challenge from the
mice described in Fig. 1. Infectious HSV-2 was detected as described in
Materials and methods. The number of ganglia or spinal cord samples with
infectious virus per total tissue samples is indicated above the data bar for
each group. An asterisk indicates significant differences in the incidence of
acute infection compared to ivag-immunized mice ( P < 0.01). The results
shown are from one representative experiment of two experiments
performed.
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ivag-immunized mice
Previous studies have demonstrated the importance of
cell-mediated immunity in protection of the genital tract
(Dudley et al., 2000; Kuklin et al., 1998; Milligan et al.,
1998). To directly compare the level of antigen-specific T
cell immunity elicited by these routes of immunization,
HSV-specific T cells present in iliac lymph nodes andTable 1
Quantification of HSV-specific T cells in the genital tracts of HSV-immunized m
Experiment Day of cell harvest Strain Immunization
1 Prechallenge B6 I.n.
Ivag
None
2 Prechallenge B6 I.n.
Ivag
None
3 Day 1 after challenge B6 I.n.
Ivag
None/HSV Challenge
3 Day 3 after challenge B6 I.n.
Ivag
None/HSV Challenge
None/No Challenge
4 Day 3 after challenge B6 I.n.
Ivag
None/No Challenge
5 Day 3 after challenge AMT I.n.
Ivag
None/HSV Challenge
None/No Challenge
a Results are expressed as the mean number of IFN-g secreting cells (SC)/iliac ly
b Results are expressed as the total number of IFN-g secreting cells (SC)/106 gengenital epithelium were quantified by ELISPOT analysis
at 4 weeks after a single HSV-2 tk immunization by the
i.n. or ivag route. As shown in Table 1, experiments 1 and
2, HSV-specific T cells were detected in iliac lymph nodes
and vaginal epithelium of B6 mice 4 weeks after ivag
immunization with HSV-2 tk. Antigen-specific T cells
were also detected in genital (iliac) lymph nodes of i.n.-
immunized mice although at levels approximately one-half
that of ivag-immunized mice. HSV-specific T cells were
detected at very low levels in the genital epithelium of i.n.-
immunized mice. The majority of antigen-specific T cells in
both i.n.- and ivag-immunized mice secreted IFN-g com-
pared to IL-4 (G. Milligan, unpublished observations),
suggesting a predominant Th1-type response in both im-
munization groups. The number of antigen-specific T cells
in iliac lymph nodes of both i.n.- and ivag-immunized mice
increased between days 1 and 3 after challenge (Table 1,
experiments 3 and 4) and was detected at much higher
levels compared to nonimmune, unchallenged and nonim-
mune, HSV-2 challenged mice. Similarly, the virus-specific
T cell response increased in the genital epithelium of both
immunization groups. However, HSV-specific T cell fre-
quencies were consistently greater in ivag-immunized mice
(Table 1, experiments 3 and 4).
Cell-mediated responses elicited by i.n immunization of
lMT mice fail to protect the genital epithelia or sensory
ganglia
We had previously demonstrated that ivag immunization
of B cell-deficient AMT mice resulted in vigorous cell-
mediated responses capable of quickly clearing HSV-2 fromice
Total IFN-g SC/iliac
lymph nodea
Genital tract IFN-g
SC/106 MNCb
Total IFN-g
SC/digestb
1800 F 470 50 50
3610 F 660 160 160
10 F 0 10 10
680 F 230 30 20
1720 F 350 150 150
10 F 0 20 10
2070 F 620 60 350
6500 F 2070 170 850
d 40 F 30 0 0
22270 F 1610 120 1860
22800 F 3420 300 2310
d 4830 F 1190 0 0
0 F 0 0 0
9660 F 1950 90 630
17280 F 4700 1610 7260
0 F 0 0 0
5520 F 1120 560 9500
12070 F 1780 3290 48360
d 2060 F 650 140 650
30 F 20 0 0
mph node of individual mice.
ital tract digest cells.
Fig. 4. Cell-mediated immunity elicited by i.n. immunization of AMT mice
fails to protect the sensory ganglia and spinal cords against acute HSV-2
infection. Tissues were removed from the mice described in Fig. 3 on day 7
after ivag HSV-2 challenge. Sensory ganglia and spinal cords from the
lumbosacral region were dissected and homogenized to detect and quantify
infectious HSV-2. The incidence of tissue samples with infectious HSV-2
per total samples is indicated above each data bar and incidence values
significantly different than ivag-immunized mice are marked with an
asterisk ( P < 0.01).
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used AMT mice to directly test the efficacy of cell-mediated
responses elicited by i.n. immunization compared to ivag
immunization. As shown in Fig. 3, HSV-2 titers remained
high and virus was not cleared from the vaginal epithelium
of nonimmune mice. Ivag-immunized AMT mice could be
reinfected with HSV-2, but virus titers dropped daily and
virus was cleared from the vaginal epithelium by day 6 after
challenge. HSV-2 titers in i.n.-immunized AMT mice were
significantly higher compared to ivag-immunized mice on
days 1–4, 6, and 7 (P < 0.01) and virus was detected in the
genital tract through day 7 after challenge.
Cell-mediated immunity elicited by ivag immunization of
AMT mice with HSV-2 tk has also been shown to provide
substantial protection against acute HSV-2 infection of the
sensory ganglia and spinal cords (Dudley et al., 2000).
Similar results were obtained in the current study (Fig. 4).
Infectious HSV-2 was detected in the sensory ganglia and
spinal cords of one of seven ivag-immunized mice on day 7
after ivag challenge with 104 PFU HSV-2 strain 186. By
contrast, infectious virus was detected at high titer at these
sites in all i.n.-immunized (9/9) and nonimmune (7/7) mice.
Similar results were obtained following ivag challenge with
5  105 PFU HSV-2 strain 186 (G. Milligan, unpublished
results). Taken together, the results of these studies suggested
that i.n. immunization provided insufficient cell-mediated
protection to effectively halt virus replication in the genital
tract and consequent spread to the sensory ganglia and
central nervous system.Fig. 3. Diminished protection of the genital tracts of i.n.-immunized AMT
mice. Groups of 8–10 AMT mice were immunized by ivag or i.n.
inoculation with HSV-2 tk . After 4 weeks, immune mice and eight
unimmunized AMT mice were challenged ivag with 104 PFU HSV-2 strain
186. Vaginal swabs were taken daily to determine virus titer. Data points
marked with asterisks are significantly different compared to ivag-
immunized mice (*P < 0.05; **P < 0.01). Similar results were obtained
in an experiment of identical design in which mice were challenged with
5  105 PFU HSV-2 strain 186.As shown in Table 1, experiment 5, HSV-specific T cells
were detected in iliac lymph nodes and genital epithelium of
i.n.-immunized AMT mice 3 days after ivag HSV-2 chal-
lenge at frequencies approximately four times greater than
in nonimmune or HSV-2 challenged mice. However, ivag
immunization resulted in an approximate 6-fold increase in
the frequency of HSV-specific T cells in the genital tract
compared to i.n.-immunized mice. Therefore, HSV-specific
T cells were present in i.n.-immunized mice at the site of
HSV-2 infection, although apparently in insufficient numb-
ers to fully protect the genital tract and prevent virus spread
to the sensory ganglia and spinal cords.
Restoration of protection of the genital tract in i.n.
-immunized lMT mice by passive transfer of HSV-specific
antibody
HSV-specific antibody was passively transferred to i.n.-
immunized AMT mice to determine if specific antibody
could restore immune protection of the genital epithelium
and sensory ganglia. HSV-specific serum IgG titers after
transfer were approximately 15 Ag/ml. This concentration
was within the range of HSV-specific serum IgG levels we
normally observed in ivag- or i.n.-immunized B6 mice
(4.5–25.0 Ag/ml HSV-specific IgG). Ivag-immunized AMT
mice cleared virus from the vaginal epithelium by day 4
after ivag HSV-2 challenge (Fig. 5). Nonimmune mice
receiving normal mouse serum were unable to clear the
challenge virus and titers were significantly higher com-
pared to ivag-immunized mice on days 2–6 after chal-
Fig. 5. Passive transfer of HSV-immune antibodies to i.n.-immunized AMT mice restores protection to the genital tract. Groups of 8 AMT mice were ivag-
immunized and 16-AMT mice were i.n.-immunized with HSV-2 tk . After 4 weeks, groups of eight i.n.-immunized and eight nonimmunized mice received
either HSV-immune serum or normal serum i.p. Three days later, mice were ivag-challenged with 104 PFU HSV-2 strain 186. Vaginal swabs were taken daily
to determine HSV-2 titer. Data points marked with an asterisk are significantly different compared to ivag-immunized mice (*P < 0.05; **P < 0.01). The
results shown are from one representative experiment of two experiments performed.
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nonimmune mice did not confer protection to the genital
epithelium. Virus titers in i.n.-immunized mice receiving
normal mouse serum were also significantly higher on
days 2–7 compared to ivag-immunized mice. However,
transfer of immune serum to i.n.-immunized mice resulted
in clearance of the virus similar to that in ivag-immunized
mice.
Augmentation of protection of the sensory ganglia in
i.n.-immunized lMTmice by passive transfer of HSV-specific
antibody
HSV immune serum was passively transferred to i.n.-
immunized AMT mice to determine if specific antibody
could similarly enhance immune protection against acuteTable 2
Transfer of HSV-immune serum augments protection of the sensory ganglia conf
AMT mice Transferred Day 7
serum
Incidencea pfu/g tiss
(log 10)b
Nonimmune Normal 8/8 4.67 F 0
Nonimmune Immune 3/4 1.42 F 0
I.n. immune Normal 4/4 2.6 F 0
I.n. immune Immune 0/8 0
Ivag
immune
None 1/8 0.3 F 0
a The incidence of acute infection of the sensory ganglia is presented as the numbe
mice tested.
b Data are presented as the mean pfu/g ganglia tissue from all mice tested.
c Total incidence of acute infection for days 7 and 8. Values marked with an ast
receiving immune serum.infection of the sensory ganglia in these animals (Table 2).
Infectious HSV-2 was detected in the sensory ganglia of all
nonimmune mice receiving normal serum.
Although transfer of HSV immune serum to nonimmune
mice failed to protect the genital epithelium (Fig. 5), the
infectious virus was detected in the sensory ganglia of 50%
of nonimmune mice (days 7 and 8 after challenge) that
received HSV immune serum, suggesting transfer of specif-
ic antibody alone provided partial protection of the sensory
ganglia. As shown previously (Dudley et al., 2000; and Fig.
4), the cell-mediated immune response elicited by ivag
immunization provided high levels of protection against
acute infection of the sensory ganglia in the absence of
HSV-specific antibody. However, the sensory ganglia of
i.n.-immunized mice were not protected against challenge in
the absence of HSV-specific antibody. Protection of i.n.-erred by HSV-specific cell mediated responses
Day 8 Total
ue Incidence pfu/g tissue
(log 10)
incidencec
.17 5/5 3.83 F 0.2 13/13*
.67 2/6 0.81 F 0.68 5/10*
.7 8/8 3.3 F 0.29 12/12*
0/8 0 0/16
.3 1/8 0.6 F 0.6 2/16
r of mice with detectable infectious HSV-2 in the sensory ganglia/number of
erisk are significantly different ( P < 0.01) compared to i.n. immune mice
G.N. Milligan et al. / Virology 318 (2004) 507–515512immunized mice was restored by the transfer of immune
sera as demonstrated by the failure to detect infectious virus
in the sensory ganglia in any of the mice.Discussion
The aim of the current study was to determine if the route
of immunization affected the level of cell-mediated protec-
tion afforded to the genital tract and sensory ganglia against
ivag HSV-2 challenge. Numerous studies have examined
mucosal delivery of vaccines to protect the genital tract
against sexually transmitted diseases. The rationale for such
studies is based largely on the concept of a common mucosal
immune system (Mestecky et al., 1994). Intranasal immuni-
zation has been commonly utilized as a means of mucosal
vaccine delivery to provide immune protection to local and
distal mucosal surfaces due to the ease and convenience of
inoculation at this site. Results of studies by several inves-
tigators have demonstrated different degrees of protection
against genital HSV challenge as a result of i.n. immuniza-
tion with adenovirus vectors expressing HSV glycoprotein B
(gB) (Gallichan and Rosenthal, 1998), attenuated strains of
HSV-2 (Parr and Parr, 1999), or plasmid DNA encoding
HSV gB (Kuklin et al., 1997). In agreement with these
studies, a single i.n. or ivag immunization of normal mice
with HSV-2 tk provided nearly equivalent levels of pro-
tection to the genital tract as measured by elimination of
challenge virus from the genital epithelia.
We extended these results by comparing protection of
the sensory ganglia against HSV-2 challenge following i.n.
or ivag immunization and examining the role of cell-
mediated and antibody responses in the protection elicited
by these routes of immunization. Infectious virus was not
detected in the sensory ganglia of mice immunized by either
route, suggesting a high degree of protection against acute
infection of the sensory ganglia. In a clinically relevant
measure of vaccination efficacy, protection against the
establishment of latency was similar in mice immunized
by either route. Therefore, the route of immunization had no
apparent affect on the level of protection measured at the
site of initial HSV infection or at the site of HSV latency.
However, the results of the current study provide evidence
that the mechanism by which protection of these sites was
achieved may be different following i.n. compared to ivag
immunization.
Recent studies utilizing i.n. immunization of recombinant
gB (Gallichan et al., 2001) or systemic (footpad) delivery of
gB peptide (Gierynska et al., 2002) with CpG oligodeox-
ynucleotide adjuvant demonstrated the presence of HSV-
specific T cells in the genital tract within 2–3 days after ivag
HSV challenge. The present study extended these findings
by demonstrating that i.n. immunization resulted in the
presence of small numbers of HSV-specific T cells not only
in secondary lymphoid tissues draining the genital tract but
also in the genital tract before HSV-2 challenge. Notsurprisingly, the frequency of HSV-specific T cells detected
in the genital tracts of ivag-immunized mice was 3–5-fold
higher than i.n.-immunized mice. These results are similar to
previous findings demonstrating that the presence of anti-
gen-specific cells is commonly higher at the site of mucosal
inoculation compared to more distal mucosal surfaces
(Hopkins et al., 1995; Rudin et al., 1998). The frequencies
of HSV-specific T cells in the genital tracts of both ivag- and
i.n.-immunized mice increased following ivag HSV-2 chal-
lenge; however, the highest frequencies were detected in
ivag-immunized mice. The ratio of HSV-specific IFN-g/IL-
4-secreting cells was not different between i.n.- and ivag-
immunized mice, suggesting that the route of priming did
not alter the type of cell-mediated response (G. Milligan,
unpublished observations). It is possible that HSV-specific T
cells might have been present in the genital epithelium of
i.n.-immunized mice at levels comparable to ivag-immu-
nized mice at time points earlier than measured in the
present study (4 weeks). However, the results of the current
studies suggest that if such a population existed in i.n.-
immunized mice, it was not maintained long-term at this site
as it was in ivag-immunized mice. Taken together, these
results provide evidence that mucosal immunization via the
i.n. route elicits antigen-specific T cells that home to and
reside within the genital tract although at lower levels than
achieved by ivag immunization.
Immunization of AMT mice allowed the direct assess-
ment of the level of protection provided by the T cell
response elicited by i.n. immunization. Previous studies
had shown that ivag immunization of AMT mice resulted
in high levels of cell-mediated protection to the vaginal
epithelia and sensory ganglia (Dudley et al., 2000) provid-
ing a basis for comparison of protection afforded by
alternate immunization routes. Although HSV-specific T
cells were readily detected in the genital tract 3 days after
challenge of i.n.-immunized AMT mice, elimination of the
challenge virus from the genital tract was impaired com-
pared to ivag-immunized mice, and the virus spread rapidly
to and was not controlled in the sensory ganglia. Thus, the
cell-mediated response elicited by i.n. immunization was by
itself insufficient to protect the genital epithelium. However,
the response was sufficient for protection in the presence of
HSV-specific antibody. Passive transfer of HSV-immune
serum to i.n.-immunized AMT mice conferred immune
control of the infection in both the genital tract and sensory
ganglia. Antibody alone was unable to confer protection
because transfer of immune serum to nonimmune mice did
not alter clearance of virus from the vagina. The underlying
mechanism by which immune antibodies acted with cellular
immune elements to enhance elimination of virus from the
genital tracts of i.n.-immunized AMT mice is unclear and is
the subject of ongoing study. It is possible that specific
antibodies act independently of the cellular response by
limiting the number of genital epithelial cells that become
infected, thus allowing more rapid clearance of the virus by
existing genital T cells. Alternatively, as proposed by
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cally with immune T cells to protect the genital tract. A
reasonable hypothesis is that a specific antibody acts in
concert with innate components such as neutrophils or
macrophages to clear extracellular virus and infected cells
from the genital tract. Activation of these innate effector
cells by antigen-specific T cells would most likely be
required as many neutrophils and macrophages are detected
in the vaginal lumen of unimmunized mice that fail to
control the infection (Milligan, 1999).
HSV-specific antibody has been shown in animal models
to limit the spread of virus to and within the peripheral
nervous system (Balachandran et al., 1982; Erlich et al.,
1987; Openshaw et al., 1979). In agreement with these
studies, transfer of immune sera to nonimmune mice pro-
vided some protection against acute HSV infection of the
sensory ganglia. Complete protection, as measured by
failure to detect infectious virus, was demonstrated in i.n.-
immunized, immune serum recipients demonstrating the
importance of cell-mediated immune mechanisms in pro-
tection of the sensory ganglia. Together, these results
demonstrate that the presence of HSV-specific antibody
enhanced the protection afforded by an otherwise insuffi-
cient HSV-specific T cell response.
The results of the current study may be relevant in
understanding the immune protection provided by natural
HSV infection in humans. Genital reinfection of humans
with HSV-2 is uncommon. This resistance may be due in
part to the long-term persistence of HSV-specific T cells in
the reproductive tract following genital HSV-2 infection
(Koelle et al., 2000). In the present study, ivag immuniza-
tion with HSV-2 tk resulted in the establishment of a
similar population of antigen-specific memory T cells in the
genital tract that provided a high level of protection to the
vaginal epithelium even in the absence of specific antibody.
In humans, the level of protection conferred by a prior oral
HSV-1 infection against a subsequent genital HSV-2 infec-
tion is uncertain (Langenberg et al., 1999). The results of
this study suggest that in addition to a virus-specific
antibody response, HSV infection of a distal mucosal site
may provide a low level of HSV-specific T cells to the
genital tract. This cell-mediated response would be pre-
dicted to be of limited efficacy in protection if the HSV-
specific antibody response waned over time or was reduced
periodically in the genital tract as a result of hormonal
influences (Gallichan and Rosenthal, 1996). This scenario
may apply also to vaccination strategies against HSV-2.
Specifically, if a sufficient T cell response is not elicited in
the genital tract following immunization, protection against
HSV disease may depend on the maintenance of high levels
of specific antibody in the genital tract. The effectiveness of
antibody to protect against neuronal spread of HSV has been
well documented in animal studies. However, the exact role
of antibody in protection of humans against HSV-2 disease
is uncertain. Specifically, HSV-subunit vaccines have not
protected the majority of recipients against HSV infectiondespite their ability to induce high levels of neutralizing
antibody (Corey et al., 1999; Stanberry et al., 2002).
Therefore, effective HSV vaccines will most likely need
to elicit both vigorous cell-mediated responses and neutral-
izing antibody responses in the genital tract to achieve high
levels of protection. Further effort is needed to determine the
most efficacious vaccine strategy for eliciting memory T cell
responses in the genital tract.Materials and methods
Virus
HSV-2 strain 333 tk was obtained from Dr. Mark
McDermott (McMaster Univ. Ontario, Canada) (McDermott
et al., 1984). Fully virulent HSV-2 strain 186 was obtained
originally from Dr. Lawrence Stanberry (University of Texas
Medical Branch, Galveston, TX). Virus stocks were prepared
by infection of Vero cell monolayers at a multiplicity of
infection of 0.01. The virus was released from cells by three
cycles of freeze thaw followed by centrifugation to remove
cell debris. Virus stocks were stored at 70 jC.
Mice
C57BL/6J (B6) mice were obtained from the Jackson
Laboratory (Bar Harbor, ME). B cell-deficient AMT mice
(Kitamura et al., 1991) on a B6 background were obtained
by permission of Dr. Werner Muller (Institute for Genetics,
Univ. of Cologne, Cologne, Germany) and were maintained
as a breeding colony. All mice were housed in sterile
microisolator cages in specific pathogen-free conditions at
the University of Texas Medical Branch-Galveston.
Immunization and virus challenge
Mice were immunized by a single ivag or i.n. inoculation
of 2  105 PFU HSV-2 tk as described previously
(Milligan and Bernstein, 1995a). Briefly, mice received
two subcutaneous injections of 3 mg medroxyprogesterone
acetate (Upjohn Company, Kalamazoo, MI) in a 1-week
period. Mice were anesthetized with sodium pentobarbital
before virus inoculation. For ivag immunization, mice were
preswabbed with a sterile calcium alginate swab and inoc-
ulated by instillation of 15 Al virus suspension into the
vaginal lumen. Vaginal challenge was performed identically
using 104 or 5  105 PFU HSV-2 strain 186. For i.n.
immunization, anesthetized mice were inoculated by instil-
lation of 10 Al of virus suspension into the nasal nares.
ELISPOT analysis
Lymphocytes were obtained from iliac lymph nodes and
genital tracts either 4 weeks after immunization with HSV-2
tk or 1–3 days after challenge with HSV-2 strain 186.
G.N. Milligan et al. / Virology 318 (2004) 507–515514Single cell suspensions of iliac lymph node cells were
prepared as described previously (Milligan et al., 1998).
Vaginae from five to eight animals were dissected and
pooled, then finely minced and digested by three separate
incubations in calcium and magnesium-free PBS (Invitrogen
Corp., Grand Island, NY) containing 1 mg/ml Dispase-
collagenase (Roche Diagnostics Corp. Indianapolis, IN)
for 30 min/incubation. Lymphocytes were enriched by
centrifugation of the digest over discontinuous Percoll
(Sigma-Aldrich, St. Louis, MO) gradients as described
previously (Milligan and Bernstein, 1995b). Typical cell
yields from digests are as follows: B6 mice 3 days post
challenge, ivag-immunized 4.5–7.5  106, i.n.-immunized
7.4–16.0  106 cells; AMT mice 3 days post challenge,
ivag-immunized 1.4  107, i.n.-immunized 1.7  107 cells;
B6 mice 1 day post challenge, ivag-immunized 5.0  106,
i.n.-immunized 1.5  107 cells; B6 mice 4 weeks post
immunization 0.5–1.0  106 cells. Lymphocytes from iliac
lymph nodes or genital tract were incubated in anti-IFN-g
antibody coated-ELISPOT plates with 5  105 mitomycin C
(Sigma-Aldrich)-treated feeder cells/well and UV-irradiated
HSV virions. After 40-h incubation, plates were developed
as described previously (Dudley et al., 2000; Milligan et al.,
1998). IFN-g secreting cells (SC) were quantified with the
aid of a dissecting microscope.
Detection and quantification of infectious HSV-2
To quantify HSV-2 present in the vagina, mice were
swabbed daily with moist calcium alginate swabs that were
stored at 70 jC in 1 ml of titration media until titration on
Vero cell monolayers as described previously (Milligan and
Bernstein, 1995a). To quantify HSV-2 present in the sensory
ganglia and spinal cords, these tissues were dissected,
weighed, homogenized in 1 ml cold titration media, and
stored frozen at 70 jC. Serial dilutions of homogenates
were plated on Vero cell monolayers.
Passive transfer of serum antibody
Immune serum was prepared by ivag inoculation with
HSV-2 tk followed 4 weeks later by ivag challenge with
HSV-2 strain 186 as described previously (Dudley et al.,
2000). Mice received a single intraperitoneal injection of 0.3
ml of HSV-immune serum (1:3 dilution) 3 days before HSV
challenge to achieve an average serum concentration of 15
Ag/ml HSV-specific IgG in recipient mice. This concentra-
tion falls into the range of HSV-specific IgG normally
detected in HSV-immunized B6 mice. An equivalent vol-
ume of diluted normal mouse serum was injected as a
control.
Statistical analysis
Data were analyzed by one-way ANOVA with the
Bonferroni correction for multiple groups. Incidence ofinfection was compared among groups using Fisher’s exact
test (two-tailed).Acknowledgments
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